| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/29/2008 | CA2323315C Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds |
| 07/29/2008 | CA2275371C Phenylethylamine derivatives |
| 07/29/2008 | CA2256022C 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
| 07/29/2008 | CA2218702C Fatty acid esters as bioactive compounds |
| 07/29/2008 | CA2218096C New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds |
| 07/24/2008 | WO2008089453A2 Inhibitors of d-amino acid oxidase |
| 07/24/2008 | WO2008089201A2 Heterocyclic-substituted piperidine as orl-1 ligands |
| 07/24/2008 | WO2008089148A1 Method of treating a metabolic or neuropsychiatry disorder with a bh4 derivative prodrug |
| 07/24/2008 | WO2008088983A1 PEGYLATED Aβ FAB |
| 07/24/2008 | WO2008088900A2 Polymorphic forms of rimonabant base and processes for preparation thereof |
| 07/24/2008 | WO2008088233A1 Therapeutical uses of eslicarbazepine |
| 07/24/2008 | WO2008088047A1 Method for glycosylation of flavonoid |
| 07/24/2008 | WO2008088039A1 Stabilized medicinal composition containing donepezil, method of producing the same and method for stabilization |
| 07/24/2008 | WO2008087936A1 Condensed tetrahydroquinoline derivative and use thereof for medical purposes |
| 07/24/2008 | WO2008087933A1 NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON IϰB KINASE β |
| 07/24/2008 | WO2008087882A1 Intragastric floating-type levodopa sustained-release preparation |
| 07/24/2008 | WO2008087704A1 Composition for improving brain function |
| 07/24/2008 | WO2008087529A1 Nicotinic acetylcholine receptor modulators |
| 07/24/2008 | WO2008087512A1 Morpholine dopamine agonists for the treatment of pain |
| 07/24/2008 | WO2008087461A2 Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis |
| 07/24/2008 | WO2008087419A2 Animal model for adhd |
| 07/24/2008 | WO2008087123A2 Use of 5-ht6 antagonists to prevent relapse into addiction |
| 07/24/2008 | WO2008086678A2 The medical use of levo-phencynonate as neuroprotective agent |
| 07/24/2008 | WO2008086573A1 Use of galanin in a method of treating neurodegenerative diseases or conditions |
| 07/24/2008 | WO2008070010A3 Hydroxylamine derivatives for the treatment of stroke |
| 07/24/2008 | WO2008068424A3 Substituted 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one derivatives, preparation thereof and use of same as cannabinoid cb1 receptor ligands |
| 07/24/2008 | WO2008067781A3 A method of purification of (s)-n-methyl-3-(1-naphtyloxy)-3-(2-thienyl) propylamine hydrochloride (duloxetine) |
| 07/24/2008 | WO2008065626A3 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors |
| 07/24/2008 | WO2008061754A8 Dietary or pharmaceutical compositions containing tricyclic diterpenes and derivatives thereof for the treatment of depression |
| 07/24/2008 | WO2008061329A3 PHα1B TOXIN, CDNA OF PHα1 B TOXIN GENE, PHARMACEUTICAL COMPOSITIONS CONTAINING PHα1B TOXIN, PROCESSES FOR THEIR OBTENTION AND PRODUCT |
| 07/24/2008 | WO2008060190A3 Ligands of 5-ht6 receptors, a pharmaceutical composition, method for the production and use thereof |
| 07/24/2008 | WO2008059949A9 Knockout animal exhibiting anxiety-like behavior |
| 07/24/2008 | WO2008056259A3 Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| 07/24/2008 | WO2008053352A3 Phenylpropionamide compounds and the use thereof |
| 07/24/2008 | WO2008051599A3 Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil |
| 07/24/2008 | WO2008045834A3 Kinase inhibitors |
| 07/24/2008 | WO2008038160A3 A substance with sedative effect for use in the treatment of neurotic disorders |
| 07/24/2008 | WO2008034087A3 Treating schizophrenia with combinations of levodopa and an antipsychotic agent |
| 07/24/2008 | WO2008021375A3 Modulators of muscarinic receptors |
| 07/24/2008 | WO2007137030A3 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
| 07/24/2008 | WO2007124757A3 Use of escitalopram for improving cognition |
| 07/24/2008 | WO2007106862A3 The use of statins to stimulate neurogenesis |
| 07/24/2008 | WO2007098462A3 Trans-fused chromenoisoquinolines, synthesis and methods for use |
| 07/24/2008 | WO2007035425A3 Cyclopropyl amines as modulators of the histamine h3 receptor |
| 07/24/2008 | US20080177248 Use of Neurotoxin Therapy for Treatment of Urologic and Related Disorders |
| 07/24/2008 | US20080177071 Process for the preparation of 2- (2- (4- (bis (4-flourophenyl) methyl) -pipe razin-1-yl) ethoxy acetic acid derivatives or corresponding salt forms thereof and intermediates therefor |
| 07/24/2008 | US20080177064 Dipeptidyl peptidase inhibitors |
| 07/24/2008 | US20080177042 Leucine-based motif and clostridial neurotoxins |
| 07/24/2008 | US20080177041 Botulinum neurotoxin type E having increased biological half-life for use treatment and prevention of autonomic, neuromuscular and pain disorders |
| 07/24/2008 | US20080177037 Leucine-based motif and clostridial neurotoxins |
| 07/24/2008 | US20080176963 administering dopamine receptor agonist in conjunction with inhibitors of endocannabinoid degradation, for the treatment of Parkinson's disease; synergistic |
| 07/24/2008 | US20080176961 Phosphodiesterase acitvity and regulation of phosphodiesterase 1-B-mediated signaling in brain |
| 07/24/2008 | US20080176950 Treatments Using Venlafaxine |
| 07/24/2008 | US20080176949 Form V can be formed by crystallization from various solvents rather than by sublimation; depression |
| 07/24/2008 | US20080176944 Elongase Genes and Uses Thereof |
| 07/24/2008 | US20080176939 Compounds which inhibit beta-secretase activity and methods of use thereof |
| 07/24/2008 | US20080176925 Toluene sulfonic acid salt of a therapeutic compound and pharmaceutical compositions thereof |
| 07/24/2008 | US20080176924 Derivatives of 4,5-diarylpyrrole, preparation method thereof and use of same in therapeutics |
| 07/24/2008 | US20080176922 Uses of 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssris |
| 07/24/2008 | US20080176917 Schizophrenia; bioavailability, solubility, brain penetrancy; in vivo half life; synthesis; such as 3-[3-({4-methyl-5-[4-(pentafluoro-6-sulfanyl)phenyl]-4H-1,2,4-triazol-3-yl}thio)propyl]-1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexane |
| 07/24/2008 | US20080176915 Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics |
| 07/24/2008 | US20080176914 Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| 07/24/2008 | US20080176913 Transdermal compositions of pramipexole having enhanced permeation properties |
| 07/24/2008 | US20080176911 2-{2-[2-hydroxy(3-methyl)butyrylamino]pentanoyl}amino-5-(1-methylethyl-4-(3-phenyl-1,2,4-oxadiazol-5-yl)thiazole; neurodegenerative diseases: senile dementia, Alzheimer's and Parkinson's diseases, Down's syndrome, amyloid angiopathy, cerebrovascular disorders, Pick's disease, post-traumatic dementias |
| 07/24/2008 | US20080176907 NOS Inhibitors For Treatment Of Motor Deficit Disorders |
| 07/24/2008 | US20080176904 Such as 1-(2,2-dimethylpropyl)-4-propyl-5-{4-[4-(1H-tetrazol-5-yl)phenoxy]butoxy}-1H-indole; neurological and psychiatric disorders |
| 07/24/2008 | US20080176903 Novel Compounds with Analgesic Effect |
| 07/24/2008 | US20080176899 Such as 1-Benzo[1,3]dioxol-5-yl-cyclopropanecarboxylic acid [5-(2-methoxy-pyridin-3-ylmethyl)-thiazol-2-yl]-amide 5-(2-Methoxy-pyridin-3-ylmethyl)-thiazol-2-ylamine; cystic fibrosis transmembrane conductance regulator disorders |
| 07/24/2008 | US20080176897 Substituted Quinolone Carboxylic Acids, Their Derivatives, Site of Action, And Uses Thereof |
| 07/24/2008 | US20080176890 Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| 07/24/2008 | US20080176887 Method for Decreasing Nicotine and Other Substance Use in Humans |
| 07/24/2008 | US20080176882 Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
| 07/24/2008 | US20080176873 Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria |
| 07/24/2008 | US20080176868 Preparation and use of compounds as protease inhibitors |
| 07/24/2008 | US20080176867 e.g., N-[[5-(4-bromophenyl)-4-(2,4-dichlorophenyl)pyrimidin-2-yl]methyl]-3-(trifluoromethyl)benzenesulfonamide; cannabinoid receptor modulator; metabolic and gastrointenstinal disorders, antidiabetic, antiinflammatory, analgesic agent; neurodegenerative diseases |
| 07/24/2008 | US20080176864 [4-(3-Methoxy-phenyl)-4-oxo-butyl]-carbamic acid tert-butyl ester; Age related functional decline, osteoporosis, osteopenia, bone fractures, male and female sexual dysfunction, erectile dysfunction, depression, prostate cancer, decreased cognitive ability, or lethargy |
| 07/24/2008 | US20080176862 New Compounds 617 |
| 07/24/2008 | US20080176856 Novel Alkyl Substituted Piperidine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors |
| 07/24/2008 | US20080176854 Nitro-Substituted Phenyl-Piperazine Compounds, Their Preparation and Use in Medicaments |
| 07/24/2008 | US20080176846 e.g. 3-(5-amino-2-methylphenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one; protein kinase inhibitor; antiinflammatory, anticarcinogenic, antiallergen, antidiabetic, antiischemic, hypotensive agent |
| 07/24/2008 | US20080176843 Modulators of muscarinic receptors |
| 07/24/2008 | US20080176841 (amidomethyl-amido)-(carboxy/amido)epoxide derivatives; cathepsin inhibitor; antiinflammatory, anticarcinogenic, antidiabeticagent, antiallergen, autoimmune and neurodegenerative disorders |
| 07/24/2008 | US20080176837 Treatment of Pain |
| 07/24/2008 | US20080176832 Pyrazolo [3,4-D]Azepine Derivatives as Histamine H3 Antagonists |
| 07/24/2008 | US20080176825 Oral Neurotherapeutic Cefazolin Compositons |
| 07/24/2008 | US20080176822 Novel composition for treating metabolic syndrome |
| 07/24/2008 | US20080176821 phosphoryl-di(glutamate dibenzylester or dihydroxyamide) derivatives; neuroleptic agent, neurodegenerative diseases, neuropathic pain, epilepsy, ischaemia, schizophrenia, amyotrophic lateral sclerosis, Alzheimer's, Parkinson, Huntington diseases; |
| 07/24/2008 | US20080176816 Method of making and using an adenosine analogue |
| 07/24/2008 | US20080176806 Therapeutic uses of tri-, tetra-, penta-, and polypeptides |
| 07/24/2008 | US20080176803 or Nicastrin complex with the novel protein Sambiasin; drugs screening, drug targets, diagnosis or prognosis of Alzheimer's disease; neurodegenerative diseases and developmental disorders caused by defects in the Notch pathway; fusion protein |
| 07/24/2008 | US20080176795 administering human H3 relaxin, carriers, diluents and/or excipients; anxiolytic agents; hormones |
| 07/24/2008 | US20080176308 Of tetrahydroacridines and tetrahydroquinolinones which are acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists; cognitive defects; Alzheimer's disease; Parkinson's disease |
| 07/24/2008 | US20080175932 Method for Decreasing Nicotine and Other Substance Use in Humans |
| 07/24/2008 | US20080175924 System and Method For Diagnosis of Neuropsychiatric Disorders |
| 07/24/2008 | US20080175909 Delivery device containing venlafaxine and memantine and method of use thereof |
| 07/24/2008 | US20080175903 Subsedative dosage form of zopiclone optical isomer; instantaneous and sustained release |
| 07/24/2008 | US20080175902 Methods for slowing the progression of multiple sclerosis |
| 07/24/2008 | US20080175895 System, devices, and methods for iontophoretic delivery of compositions including antioxidants encapsulated in liposomes |
| 07/24/2008 | US20080175894 Methods of treating neurological conditions with hematopeitic growth factors |
| 07/24/2008 | US20080175873 cores comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol, gelling agents and excipients, having sustained release coatings; higher bioavailability and side effect reduction |